Novartis, SciNeuro to work together on preclinical amyloid-targeting drug for Alzheimer’s

No­var­tis is spend­ing $165 mil­lion up­front to li­cense a pre­clin­i­cal amy­loid-tar­get­ing pro­gram for Alzheimer’s dis­ease from SciNeu­ro.

The com­pa­nies will joint­ly ad­vance the pro­gram through …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.